HUE056301T2 - Szubsztituált karbamidszármazék és annak gyógyászatban történõ alkalmazása - Google Patents

Szubsztituált karbamidszármazék és annak gyógyászatban történõ alkalmazása

Info

Publication number
HUE056301T2
HUE056301T2 HUE18831929A HUE18831929A HUE056301T2 HU E056301 T2 HUE056301 T2 HU E056301T2 HU E18831929 A HUE18831929 A HU E18831929A HU E18831929 A HUE18831929 A HU E18831929A HU E056301 T2 HUE056301 T2 HU E056301T2
Authority
HU
Hungary
Prior art keywords
medicine
salt
urea derivative
substituted urea
substituted
Prior art date
Application number
HUE18831929A
Other languages
English (en)
Inventor
Liang Chen
Chengxi Li
Bing Liu
Yingjun Zhang
Changchung Cheng
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of HUE056301T2 publication Critical patent/HUE056301T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE18831929A 2017-07-13 2018-07-11 Szubsztituált karbamidszármazék és annak gyógyászatban történõ alkalmazása HUE056301T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710569633 2017-07-13

Publications (1)

Publication Number Publication Date
HUE056301T2 true HUE056301T2 (hu) 2022-02-28

Family

ID=65001137

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18831929A HUE056301T2 (hu) 2017-07-13 2018-07-11 Szubsztituált karbamidszármazék és annak gyógyászatban történõ alkalmazása

Country Status (11)

Country Link
US (1) US11213529B2 (hu)
EP (1) EP3652172B1 (hu)
JP (1) JP7202350B2 (hu)
KR (1) KR102566089B1 (hu)
CN (1) CN109251181B (hu)
AU (1) AU2018299536B2 (hu)
CA (1) CA3069773A1 (hu)
DK (1) DK3652172T3 (hu)
ES (1) ES2889749T3 (hu)
HU (1) HUE056301T2 (hu)
WO (1) WO2019011264A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022039421A1 (ko) * 2020-08-18 2022-02-24 재단법인대구경북과학기술원 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
CN112785582B (zh) * 2021-01-29 2024-03-22 北京百度网讯科技有限公司 热力图生成模型的训练方法、装置、电子设备和存储介质

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060969A1 (en) * 2003-12-24 2005-07-07 Astrazeneca Ab Pyrimidines with tie2 (tek) activity
ATE415970T1 (de) 2003-12-24 2008-12-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
CA2696776C (en) 2007-09-19 2015-12-15 Ambit Biosciences Corporation Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
CN102153553A (zh) * 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物
HUE046008T2 (hu) 2014-07-17 2020-02-28 Sunshine Lake Pharma Co Ltd I-(5-terc-butil)-izoxazol-3-il)-3-(4-((feniI)-etinil)-fenil)-kabamid származékok, valamint az ezekkel rokon vegyületek FLT-3 inhibitorokként rák kezelésére

Also Published As

Publication number Publication date
KR20200028442A (ko) 2020-03-16
EP3652172A1 (en) 2020-05-20
EP3652172A4 (en) 2020-11-18
JP7202350B2 (ja) 2023-01-11
CA3069773A1 (en) 2019-01-17
WO2019011264A1 (en) 2019-01-17
AU2018299536B2 (en) 2022-06-02
DK3652172T3 (da) 2021-09-20
CN109251181B (zh) 2021-08-31
KR102566089B1 (ko) 2023-08-14
US20200121690A1 (en) 2020-04-23
CN109251181A (zh) 2019-01-22
US11213529B2 (en) 2022-01-04
AU2018299536A1 (en) 2020-01-30
ES2889749T3 (es) 2022-01-13
JP2020526550A (ja) 2020-08-31
EP3652172B1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
IL273918A (en) Trispecific proteins and methods of use
HK1232224A1 (zh) 取代脲衍生物及其在藥物中的應用
IL249189A0 (en) Combined treatment of antibodies against human cd40 and antibodies against human pd-l1
HK1216251A1 (zh) 吡唑並吡咯烷衍生物及其治病作用
GB201616616D0 (en) Nasal drug products and methods of their use
LT3786160T (lt) Piridino dariniai ir jų terapinis panaudojimas kaip trpc6 inhibitorių
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
IL258978B (en) The use of pyrimidine and pyridine derivatives in the treatment of multiple sclerosis
IL263969A (en) Benzodioxane derivatives and their pharmaceutical use
EP3256461C0 (en) UREA AND SULFONAMIDE DERIVATIVES AS HUMAN DDX3 HELICASE INHIBITORS USEFUL IN THE TREATMENT OF VIRAL DISEASES
GB201715194D0 (en) Compounds and their therapeutic use
HK1248209A1 (zh) 尿素衍生物和其用途
ZA201805296B (en) Succinate salt of cytisine and use thereof
HUE056301T2 (hu) Szubsztituált karbamidszármazék és annak gyógyászatban történõ alkalmazása
IL261646A (en) History of urea and amide and their use as cyclophilin inhibitors
ZA202000959B (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
HK1251558A1 (zh) 新的酰亞胺衍生物及其作為藥物的用途
HK1248208A1 (zh) 尿素衍生物和其用途
PL3262069T3 (pl) Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu
LT3152193T (lt) Tetrahidroizochinolinono dariniai ir jų panaudojimas hsp70 baltymo inhibicijoje
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease